Grufity logoGrufity logo

Novocure Ltd Stock Research

NVCR

57.77USD-0.52(-0.89%)Market Closed

Market Summary

USD57.77-0.52
Market Closed
-0.89%

NVCR Alerts

NVCR Stock Price

NVCR RSI Chart

NVCR Valuation

Market Cap

5.9B

Price/Earnings (Trailing)

-64.07

Price/Sales (Trailing)

11.02

EV/EBITDA

-81.67

Price/Free Cashflow

628.74

NVCR Price/Sales (Trailing)

NVCR Profitability

Operating Margin

78.64%

EBT Margin

-15.22%

Return on Equity

-20.97%

Return on Assets

-7.77%

Free Cashflow Yield

0.16%

NVCR Fundamentals

NVCR Revenue

Revenue (TTM)

537.8M

Revenue Y/Y

-3.59%

Revenue Q/Q

-1.96%

NVCR Earnings

Earnings (TTM)

-92.5M

Earnings Y/Y

-40.99%

Earnings Q/Q

-40.36%

Price Action

52 Week Range

56.06120.03
(Low)(High)

Last 7 days

-0.3%

Last 30 days

-24.3%

Last 90 days

-15.3%

Trailing 12 Months

-27.3%

NVCR Financial Health

Current Ratio

7

Debt/Equity

1.27

Debt/Cashflow

0.09

NVCR Investor Care

Shares Dilution (1Y)

1.04%

Diluted EPS (TTM)

-0.88

Peers (Alternatives to Novocure)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
103.1B
18.4B
6.02% 5.19%
43.7
5.59
7.84% 18.25%
88.4B
6.2B
9.31% -11.96%
66.85
14.21
8.97% -22.43%
69.2B
12.7B
2.81% 11.10%
99.12
5.46
6.68% -32.95%
68.6B
19.0B
2.19% -5.22%
42.6
3.61
-0.43% -8.78%
49.2B
5.4B
6.12% -27.99%
32.34
9.15
2.86% 1.25%
MID-CAP
7.2T
489.7M
16.25% 13.06%
82.2K
16.8K
106.51% 2464.23%
10.4B
847.1M
3.66% 36.84%
-5.2K
12.31
13.32% -137.89%
5.2B
1.0B
-9.17% -24.82%
30.22
5.09
6.76% 24.45%
3.6B
410.9M
3.83% -15.78%
-30.64
8.66
27.29% -14.60%
2.7B
801.2M
11.07% -63.68%
-28.28
3.34
14.00% -707.69%
SMALL-CAP
1.6B
350.9M
7.57% 51.19%
-10.79
4.68
44.26% -5.42%
1.6B
138.6M
-27.43% 0.81%
-28.66
11.37
36.62% -10.44%
1.3B
820.0M
0.91% -12.65%
26.12
1.61
10.13% 701.59%
828.4M
239.8M
0.81% -4.01%
-21.88
3.45
-4.74% -31.15%

Financials for Novocure

Income Statement (Last 12 Months)
(In Thousands)
* denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-0.9%537,840542,624545,232537,883535,031
Gross Profit-0.9%422,973426,958429,109421,664420,154
Operating Expenses3.1%512,496496,901482,993466,715464,487
  S&GA Expenses6.5%173,658163,011154,196143,584137,057
  R&D Expenses-1.0%206,085208,196204,381197,621201,303
EBITDA-10.9%-71,181-64,170-51,211-41,264-
EBITDA Margin-11.9%-0.13*-0.12*-0.09*-0.08*-
Earnings Before Taxes-9.3%-81,846-74,861-61,977-51,856-52,075
EBT Margin-10.3%-0.15*-0.14*-0.11*-0.10*-
Interest Expenses-59.4%41.00101101101101
Net Income-13.3%-92,534-81,689-68,237-58,870-58,351
Net Income Margin-14.3%-0.17*-0.15*-0.13*-0.11*-
Free Cahsflow-52.1%9,43019,69824,08436,007-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets1.5%1,1921,1741,1631,1501,139
  Current Assets0.8%1,1121,1021,0951,0811,074
    Cash Equivalents-52.7%115244368192209
  Inventory9.6%29.0027.0030.0029.0024.00
  Net PPE9.9%33.0030.0027.0025.0023.00
Liabilities3.0%750729721714729
  Current Liabilities12.5%159141135128143
  Long Term Debt-562----
    LT Debt, Non Current0.1%566565564563562
Shareholder's Equity-0.9%441445442436410
  Retained Earnings-5.0%-778-741-714-690-685
  Additional Paid-In Capital2.8%1,2221,1891,1581,1281,100
Accumulated Depreciation-22.00----
Shares Outstanding0.2%105105105104104
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-37.0%31.0049.0051.0061.0083.00
  Share Based Compensation7.4%10710099.0010195.00
Cashflow From Investing72.6%-139-510-58.04-216-144
Cashflow From Financing-1.5%15.0016.0015.0021.0026.00

Risks for NVCR

What is the probability of a big loss on NVCR?

99.6%


Probability that Novocure stock will be more than 20% underwater in next one year

80%


Probability that Novocure stock will be more than 30% underwater in next one year.

43.9%


Probability that Novocure stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does NVCR drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Novocure was unfortunately bought at previous high price.

Drawdowns

Returns for NVCR

Cumulative Returns on NVCR

24.1%


7-Year Cumulative Returns

22.3%


5-Year Cumulative Returns

-3.8%


3-Year Cumulative Returns

What are the long-term rolling returns for NVCR?

FIve years rolling returns for Novocure.

Annualized Returns

Which funds bought or sold NVCR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-23
ETF MANAGERS GROUP, LLC
sold off
-100
-3,751,000
-
-%
2023-03-17
American Portfolios Advisors
reduced
-4.76
180
4,559
-%
2023-03-10
BAILLIE GIFFORD & CO
reduced
-0.56
-27,137,200
650,163,000
0.68%
2023-03-07
Nordwand Advisors, LLC
new
-
111,125,000
111,125,000
13.86%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-85.97
-600,000
93,000
-%
2023-03-03
TIAA, FSB
unchanged
-
-7,718
215,282
-%
2023-02-28
Voya Investment Management LLC
added
8.68
1,100,570
23,496,600
0.03%
2023-02-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
-241,000
6,733,000
0.07%
2023-02-21
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
unchanged
-
-330
14,670
-%
2023-02-21
MACQUARIE GROUP LTD
added
13.25
502,148
5,886,150
0.01%

1–10 of 40

Latest Funds Activity

Are funds buying NVCR calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own NVCR
No. of Funds

Novocure News

Nasdaq

Noteworthy Tuesday Option Activity: PFE, GLPI, NVCR.

Nasdaq,
3 hours ago

Seeking Alpha

Nasdaq

The Motley Fool

2 Best Defensive Stocks to Buy in March.

The Motley Fool,
20 days ago

Schedule 13G FIlings of Novocure

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2023
capital international investors
7.8%
8,155,909
SC 13G/A
Feb 13, 2023
capital world investors
12.3%
12,899,395
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
9.10%
9,547,336
SC 13G/A
Jan 31, 2023
blackrock inc.
7.2%
7,605,425
SC 13G/A
Jan 23, 2023
baillie gifford & co
8.45%
8,863,842
SC 13G/A
Apr 11, 2022
fmr llc
-
0
SC 13G/A
Feb 11, 2022
capital world investors
12.3%
12,723,214
SC 13G/A
Feb 11, 2022
capital international investors
11.1%
11,531,075
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A

NVCR Fair Value

Novocure fair value in different scenarios

The table shows the Fair Value estimates for Novocure for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

1.42

-97.54%

2.29

-96.04%

4.40

-92.38%

8.72

-84.91%

17.51

-69.69%
Current Inflation

1.37

-97.63%

2.14

-96.30%

3.97

-93.13%

7.67

-86.72%

15.15

-73.78%
Very High Inflation

1.31

-97.73%

1.96

-96.61%

3.46

-94.01%

6.44

-88.85%

12.43

-78.48%

Historical Novocure Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Novocure

View All Filings
Date Filed Form Type Document
Mar 07, 2023
4
Insider Trading
Mar 07, 2023
4
Insider Trading
Mar 07, 2023
4
Insider Trading
Mar 07, 2023
4
Insider Trading
Mar 07, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading

Latest Insider Trading transactions for NVCR

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-07
Leonard Frank X
sold
-625,205
75.1629
-8,318
president, cns cancers us
2023-03-03
GROENHUYSEN WILHELMUS CM
acquired
-
-
51,986
chief operating officer
2023-03-03
Weinberg Uri
acquired
-
-
32,766
chief innovation officer
2023-03-03
Shah Pritesh
sold
-1,631,410
76.1594
-21,421
chief growth officer
2023-03-03
Cordova Ashley
acquired
-
-
11,808
chief financial officer
2023-03-03
Burke William Patrick
sold
-45,162
76.1594
-593
chief human resources officer
2023-03-03
Leonard Frank X
acquired
-
-
11,808
president, cns cancers us
2023-03-03
Leonard Frank X
sold
-159,859
77.6391
-2,059
president, cns cancers us
2023-03-03
GROENHUYSEN WILHELMUS CM
sold
-1,952,350
76.1594
-25,635
chief operating officer
2023-03-03
Shah Pritesh
acquired
-
-
47,182
chief growth officer

1–10 of 50

Asaf Danziger
1170
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields (TTFields) devices for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and malignant pleural mesothelioma. The company markets its products in the European Union, the United Kingdom, Japan, and internationally. It has a clinical study collaboration agreement with MSD to study TTFields together with KEYNOTE, an anti-PD-1 therapy; and a strategic collaboration with Zai Lab (Shanghai) Co., Ltd. to commercialize its products in Greater China and establishes a development partnership intended to accelerate the development of TTFields in multiple solid tumor cancer indications. NovoCure Limited was incorporated in 2000 and is based in Saint Helier, Jersey.

NVCR Income Statement

2022-12-31
Consolidated statements of operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]   
Net revenues$ 537,840$ 535,031$ 494,366
Cost of revenues114,867114,877106,501
Gross profit422,973420,154387,865
Operating costs and expenses:   
Research, development and clinical studies206,085201,303132,010
Sales and marketing173,658137,057118,017
General and administrative132,753126,127107,437
Total operating costs and expenses512,496464,487357,464
Operating income (loss)(89,523)(44,333)30,401
Financial (expenses) income, net7,677(7,742)(12,299)
Income (loss) before income taxes(81,846)(52,075)18,102
Income tax10,6886,276(1,706)
Net income (loss)$ (92,534)$ (58,351)$ 19,808
Basic net income (loss) per ordinary share (in usd per share)$ (0.88)$ (0.56)$ 0.20
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)104,660,476103,433,274100,930,866
Diluted net income (loss) per ordinary share (in usd per share)$ (0.88)$ (0.56)$ 0.18
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)104,660,476103,433,274108,877,648

NVCR Balance Sheet

2022-12-31
Consolidated balance sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 115,326$ 208,802
Short-term investments854,099728,898
Restricted cash508807
Trade receivables, net86,26193,567
Receivables and prepaid expenses25,95917,025
Inventories29,37624,427
Total current assets1,111,5291,073,526
Long-term assets:  
Property and equipment, net32,67822,693
Field equipment, net12,68412,923
Right-of-use assets23,59618,267
Other long-term assets11,16112,086
Total long-term assets80,11965,969
Total assets1,191,6481,139,495
Current liabilities:  
Trade payables85,19772,600
Other payables, lease liabilities and accrued expenses73,58070,002
Total current liabilities158,777142,602
Long-term liabilities:  
Long-term debt, net565,509562,216
Deferred revenues2,8786,477
Long term leases18,76212,997
Employee benefit liabilities4,4044,543
Other long-term liabilities148166
Total long-term liabilities591,701586,399
Total liabilities750,478729,001
Commitments and contingencies
Shareholders’ equity:  
Ordinary shares - No par value, Unlimited shares authorized; Issued and outstanding: 105,049,411 shares and 103,971,263 shares at December 31, 2022 and December 31, 2021 respectively;00
Additional paid-in capital1,222,0631,099,589
Accumulated other comprehensive income (loss)(2,433)(3,169)
Retained earnings (accumulated deficit)(778,460)(685,926)
Total shareholders’ equity441,170410,494
Total liabilities and shareholders’ equity$ 1,191,648$ 1,139,495